- ￥2800
- 雅吉生物
- 中国
- RE59743
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 库存：
100
- 组织来源：
细胞系
- 物种来源：
ATCC/sciencell/上海细胞库/自建细胞库
- 运输方式：
顺丰快递
- 年限：
第三代
- 生长状态：
贴壁/悬浮
- 规格：
1*106/T25瓶
| Synonyms: | IGROV-1(人卵巢子宫内膜样腺癌) |
| Disease State： | Ovarian |
| Gender: | 47 years,female |
| Prior Treatment: | Radiation and cobalt therapy of the cervix and vagina |
| Tissue: | Ovary |
| Histology: | Glandular, olymorphous, multiple differentiations epithelioma; predominantly endometrioid; with some serous clear cells and undifferentiated foci; right ovary, which was previously untreated |
| p53 Status: | 1 |
| ECAD Methylation: | 44 |
| MDR Function: | 20 |
| Arrays Using This Cell Line: | NCI60_RadiationResponse (16) |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Institution: | Institute Gustave Roussy, France |
| Comment： | N/A |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Deep Transcriptome Profiling of Ovarian Cancer Cells Using Next-Generation Sequencing Approach
transcript sequencing levels, we applied two next-generation sequencing technologies to study two ovarian chemotherapy response models: the in vitro acquired cisplatin-resistant cell line model (IGROV-1-CP and IGROV1) and the in vivo ovarian cancer tissue
Establishment of Ovarian Cancer Cell Lines
Mel/Radiother 11 IGROV1 Adenoca Primary None 12
技术资料需要更多技术资料 索取更多技术资料
